Cilo Cybin back on track for SPAC listing on the JSE
IMMEDIATE: Wednesday, 19 April 2023
Cilo Cybin back on track for SPAC listing on the JSE
IPO to be underwritten by Malaysian Group acquiring 10% equity shareholding in Cilo Cybin Pharmaceutical
Johannesburg: 19 April 2022 - Cilo Cybin Pharmaceutical (Pty) Ltd (Cilo Cybin) has announced that the ALPS Global Holding Berhad (ALPS) Group of companies, a fully integrated biotechnology research, medical and wellness company operating in Kuala Lumpur, Malaysia, has acquired a 10% equity shareholding in Cilo Cybin. The acquisition is aimed at supporting Cilo Cybin in its upcoming IPO efforts later this year. ALPS has agreed to underwrite the IPO for Cilo Cybin to ensure a listing on the JSE.
Gabriel Theron, Founder and CEO of Cilo Cybin, says his Board is delighted to have ALPS on board as a partner. “Our decision to delay the SPAC listing on the JSE in November last year proved to be both prudent and fortunate. The additional time allowed Cilo Cybin to secure a significant investment that not only paves the way to al listing on the JSE but also provides a gateway for Cilo Cybin and ALPS to jointly enter, investigate and secure new markets with a distinctively combined and strategically positioned service offering.
Cilo Cybin combines Biotech and Pharmaceutical methodologies to deliver a holistic and individualised solution that enhances health, performance and longevity through the use of technologies, apps, devices, supplementation and medication.
Commenting on ALPS acquisition of equity shareholding in Cilo Cybin, Group Chief Executive Officer and Group Chief Research Scientist of ALPS, Dr THAM Seng Kong, says he was impressed by similarities in vision between the two companies and the many potential synergies that could benefit them both.
Theron refers to Dr THAM as the main driver leading the ALPS Group to greater heights towards recognition as a global biotechnology company. “Today, ALPS has evolved into a fully integrated platform consisting of biotechnology research, medical and wellness establishments dealing with Predictive, Precision and Preventive Health Management expertise. ALPS is currently one of the most progressive Biomarker Precision Diagnostic Lab with full instrument Whole Genome Sequencing and cGMP stem cell cultivation in the ASEAN region, with a business focus on molecular cells as therapeutic entities.”
Headquartered in the heart of Kuala Lumpur’s Central Business District, ALPS’ core centres comprise ALPS Medical Centre, ALPS Wellness & Anti-Aging Centre (Aesthetic, Wellness and Anti-Aging Procedures), MyGenome Molecular Institute (Whole Genome Sequencing dealing with DNA and RNA expertise) and Celestialab (Cultivation of Cellular Products) – all engineered and designed to revitalize the individual’s health and well-being through the Precision & Preventive Ethos.
ALPS is also working cohesively with certain Universities in collaboration to set up a National Human Genes Bank, the first in Southeast Asia. There will also be Stem cell initiatives, through our expertise, to make available IPS Cells for pancreatic Beta-cell to treat Diabetes Mellitus I, Neuron cells for Alzheimer’s Disease and Parkinson’s Disease, cardiomyocytes for Heart valves etc. ALPS aim is to apply Whole Genome Sequencing and mRNA expressed gene profiling in future diagnostic testing and creation of personalized medicine. ALPS will soon be able to produce and cultivate autologous stem cells at our own premises.
ALPS will also be pivotal in the establishment of an international Research and Development Hub of renowned scientists and institutions involved in stem cell related research to use cellular therapy as therapeutic entities.
END
For more information please contact:
Jacques Verster
Email: jacques@mortimerharvey.com
Cell: 083 276 9009
EDITOR’S NOTES
About ALPS Global Holding Berhad
ALPS Global Holding Berhad (ALPS) Group of companies, is a fully integrated biotechnology research, medical and wellness company operating in Kuala Lumpur, Malaysia since 2017. ALPS’s business focuses on the belief that the use of precision and preventive medicine as therapeutic entities will drive and revolutionise the next important phases in medicine and wellness.
Today, ALPS has evolved into a fully integrated platform consisting of biotechnology research, medical and wellness establishments dealing with Predictive, Precision and Preventive Health Management expertise. ALPS has the leading-edge technology and the necessary expertise (technological resources, team of scientists, researchers, and equipment), all in place, all cutting edge and advancing with momentum.
ALPS is currently one of the most progressive Biomarker Precision Diagnostic Lab with full instrument Whole Genome Sequencing and cGMP stem cell cultivation in the ASEAN region, with a business focus on molecular cells as therapeutic entities.
Headquartered in the heart of Kuala Lumpur’s Central Business District, ALPS’ core centres comprise ALPS Medical Centre, ALPS Wellness & Anti-Aging Centre (Aesthetic, Wellness and Anti-Aging Procedures), MyGenome Molecular Institute (Whole Genome Sequencing dealing with DNA and RNA expertise) and Celestialab (Cultivation of Cellular Products) – all engineered and designed to revitalize the individual’s health and well-being through the Precision and Preventive Ethos.
ALPS is also working cohesively with certain Universities in collaboration to set up a National Human Genes Bank, the first in Southeast Asia. There will also be Stem cell initiatives, through our expertise, to make available IPS Cells for pancreatic Beta-cell to treat Diabetes Mellitus I, Neuron cells for Alzheimer’s Disease and Parkinson’s Disease, cardiomyocytes for Heart valves etc. ALPS aim is to apply Whole Genome Sequencing and mRNA expressed gene profiling in future diagnostic testing and creation of
personalized medicine. ALPS will soon be able to produce and cultivate autologous stem cells at our own premises.
ALPS will also be pivotal in the establishment of an international Research and Development Hub of renowned scientists and institutions involved in stem cell related research to use cellular therapy as therapeutic entities.
Biodata
Dr. THAM Seng Kong MD., PhD. (PRC)
Managing Director / Group Chief Executive Officer, ALPS Global Holding Berhad Dr. THAM as Group Chief Executive Officer and Group Chief Research Scientist is the main
driver leading the ALPS Group to greater heights towards recognition as a global biotechnology company.
Dr. THAM is a veteran of life sciences, with a genuine passion for the field of Cellular Therapy. He is an established member of the Malaysian Society for Stem Cell Research & Therapy (MSCRT) and the Malaysia Association for Cell Therapy (MACT). He has been involved in ongoing extensive research on anti-aging cellular therapy since 2006. He works very closely with his Swiss and Asian counterparts in advancing the human understanding of cellular therapy and is eager to share his experiences in this field.
Dr. THAM also actively participates in cancer research. One of his important scientific
breakthroughs is the discovery of a penetrating tyrosinase inhibitor to reduce the production of melanin for skin beauty and whitening. He also described in his recent publication on the successful construction of a retroviral transfection system that could be developed as a means of gene therapy for hepatic carcinoma.
Dr. THAM earned his Bachelor of Medicine from Xiamen University, Doctor of Medicine (MD) Integrated Chinese Medicine & Western Clinical Medicine (Oncology) from Guangzhou University of Chinese Medicine (GUCM). Presently, he has the privilege of treating and consulting international members of royalty, celebrities, and members of the elite. He is also well-soughtafter as an Educator on Best Practices, and dedicates his time between clinical physicians and members of the public.
Date : 08 March 2023
About Cilo Cybin
We believe the world is entering a new era of personalised healthcare, a world in whicheach person’s health and wellbeing will require bespoke, individualised andintelligently targeted interventions. Cilo Cybin aims to combine Biotech and Pharmaceutical methodologies to deliver a holistic and individualised solution that enhances health, performance and longevity through the use of technologies, apps, devices, supplementation and medication.